MAXCYTE director granted RSUs and stock options
MAXCYTE director Cynthia Collins received new equity awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
MAXCYTE director Cynthia Collins received new equity awards. On June 17, 2026, she was granted 30,421 restricted stock units, each representing one future share of common stock, and a stock option for 49,579 shares at an exercise price of $1.13 per share, expiring in 2036. Following the grant, she directly holds 111,310 shares of common stock, and the RSUs vest on June 17, 2027 if she continues serving as a director.
Insider Trade Summary
Grant/Award: 80,000 shares
Grant/Award
2 txns
Insider
Collins Cynthia
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 49,579 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 30,421 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 49,579 contracts (Direct);
Common Stock — 111,310 shares (Direct)
Footnotes (2)
- F1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F2. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.
Key Figures
RSU grant size: 30,421 RSUs
Stock options granted: 49,579 options
Option exercise price: $1.13 per share
+2 more
5 metrics
RSU grant size
30,421 RSUs
Annual grant to non-employee director on June 17, 2026
Stock options granted
49,579 options
Right to buy MAXCYTE common stock
Option exercise price
$1.13 per share
Conversion or exercise price for 49,579 options
Option expiration
June 16, 2036
Expiration date of stock option grant
Shares held after grant
111,310 shares
Common stock directly owned following transactions
Key Terms
restricted stock units ("RSUs"), Equity Grant Policy, Stock Option (right to buy), vesting
4 terms
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Equity Grant Policy financial
"This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors."
Stock Option (right to buy) financial
"Stock Option (right to buy) ... conversion_or_exercise_price: "1.1300""
vesting financial
"The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did MAXCYTE (MXCT) director Cynthia Collins receive?
Cynthia Collins received 30,421 restricted stock units and a stock option for 49,579 shares. The option has a $1.13 exercise price and expires in 2036, aligning her compensation with MAXCYTE’s long-term performance.
Are Cynthia Collins’ new MAXCYTE RSUs immediately vested?
No, the 30,421 restricted stock units vest on June 17, 2027. Vesting is conditional on her continuous service as a non-employee director, encouraging longer-term board commitment and alignment with shareholders’ interests over time.
What is the exercise price and term of Cynthia Collins’ MAXCYTE stock options?
Her stock option covers 49,579 shares of MAXCYTE common stock at a $1.13 exercise price. The option expires on June 16, 2036, providing a long-dated incentive tied to potential future share price appreciation.
Why did MAXCYTE grant these awards to Cynthia Collins?
The awards were made under MAXCYTE’s Equity Grant Policy for non-employee directors. This policy provides annual equity grants, using RSUs and options to compensate directors and better align their interests with company shareholders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
